| 2025/01/21 | 17:33:29 | Announcement in accordance with Article 22.1(3) of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies | |
| SEQ_NO |
2 |
Date of announcement |
2025/01/21 |
Time of announcement |
17:33:29 |
| Subject |
Announcement in accordance with Article 22.1(3) of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies |
| Date of events |
2025/01/21
|
To which item it meets |
paragraph 23 |
| Statement |
1.Date of occurrence of the event:2025/01/21
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name?GPMC
(2)Relationship with lender?GPMC is a subsidiary of Medeon Biodesign
which holds 89.27% of the shares.
(3)Lending limit (thousand NTD)?G171,983
(4)Starting outstanding balance (thousand NTD)?G0
(5)New loan (thousand NTD)?G165,000
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors to
allocate?GYes
(7)Outstanding balance (thousand NTD) up to the date of occurrence?G
165,000
(8)Reason for new loan (thousand NTD)?Gworking capital requirements
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content?GNone
(2)Value (thousand NTD)?G0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD)?G111,890
(2)Cumulative gains/losses (thousand NTD)?G-1,187,638
5.Method of calculation of interest:With an annual interest rate of 3%
6.For repayment, the(1)Condition(2)Date:
(1)Condition?GBased on the contract
(2)Date?GBased on the contract
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):165,000
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:9.59%
9.Sources of funds for the company to extend monetary
loans to others:Other
10.Any other matters that need to be specified:
The source of funds loaned by the Company to PMC is working capital. |
|
| 2025/01/21 | 17:15:40 | Medeon Biodesign’s Board of Directors approved incremental investment to its subsidiary Medeologix Corporation | |
| SEQ_NO |
1 |
Date of announcement |
2025/01/21 |
Time of announcement |
17:15:40 |
| Subject |
Medeon Biodesign’s Board of Directors approved incremental investment to its subsidiary Medeologix Corporation |
| Date of events |
2025/01/21
|
To which item it meets |
paragraph 20 |
| Statement |
1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):
The new common shares issued for capital increase by
Medeologix Corporation
2.Date of occurrence of the event:2025/01/21~2025/01/21
3.Volume, unit price, and total monetary amount of the transaction:
Transaction Volume: No more than 8,960,000 common shares
Issued price per share: NTD 25
Total monetary amount: No more than NTD 224,000,000
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Medeologix Corporation, the subsidiary of Medeon Biodesign
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:
Reason for choosing the related party as the trading counterparty:
The subsidiary of Medeon Biodesign
Previous owner, its relationship with the Company and the trading
counterparty, and the previous date and monetary value of transfer: N/A
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:N/A
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor’s
rights, currently being disposed of, over such related
party:N/A
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):N/A
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:
Terms of delivery or payment: Payment will be made according to the fund
raising schedule resolved by Medeologix’s board.
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Medeon Board of Director’s resolution dated 2025/1/21
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:NTD 8.92
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative number of shares held (including the current transaction):
No more than 61,774,174 shares
Cumulative monetary amount (including the current transaction):
No more than NTD 1,379,000 thousand.
Cumulative shareholding percentage: No more than 97.09%
The status of any restriction of rights (e.g., pledges): None
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Current ratio of securities investment to the total assets: 57.35%
Current ratio of securities investment to the equity attributable to
owners of the parent: 80.18%
Working capital: NTD 1,593,781 thousand.
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
Long-term Equity Investment
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:Yes
18.Date of the Board of Directors’ resolution:2025/01/21
19.Date of ratification by supervisors or approval by
the Audit Committee:2025/01/21
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:No
21.Name of the CPA firm:Horng Yow Certified Public Accountants
22.Name of the CPA:JUYU TANG
23.License no.of the CPA:
Financial-Supervisory-Securities-Corporate-0970013154
24.Whether the transaction involved in change of business model:No
25.Details on change of business model:N/A
26.Details on transactions with the counterparty for the past
year and the expected coming year:N/A
27.Source of funds:working capital
28.Any other matters that need to be specified:None |
|
| 2025/01/14 | 17:34:05 | Medeon, on behalf of its subsidiary Medeologix Corporation, announces the BOD approved the incremental investment to its subsidiary, Medeologix LLC. | |
| SEQ_NO |
3 |
Date of announcement |
2025/01/14 |
Time of announcement |
17:34:05 |
| Subject |
Medeon, on behalf of its subsidiary Medeologix Corporation, announces the BOD approved the incremental investment to its subsidiary, Medeologix LLC. |
| Date of events |
2025/01/14
|
To which item it meets |
paragraph 20 |
| Statement |
1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Medeologix LLC’s interest
2.Date of occurrence of the event:2024/02/01~2025/01/14
3.Volume, unit price, and total monetary amount of the transaction:
2024/2/1 total transaction amount: US$1,000,000
2024/11/15 total transaction amount: US$300,000
The total transaction amount: The Board of Directors of Medeologix
Corporation has set an investment cap for Medeologix LLC at no more
than US$3,000,000 within one year. The actual investment amount is
authorized to be determined by the Chairman of Medeologix Corporation
based on the operational needs of Medeologix LLC.
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Medeologix LLC, the 100%-owned subsidiary of Medeologix Corporation
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:
Reason for choosing the related party as the trading counterparty:
The 100%-owned subsidiary of Medeologix Corporation
Previous owner, its relationship with the Company and the trading
counterparty, and the previous date and monetary value of transfer: N/A
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:N/A
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor’s
rights, currently being disposed of, over such related
party:N/A
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):N/A
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:
Terms of delivery or payment: Invest according to Medeologix LLC’s
capital needs
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Resolutions of Medeologix Corporation ‘s Board of Directors dated
2024/1/17 and 2025/1/14.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:N/A
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative number of shares held (including the current transaction):N/A
Cumulative monetary amount (including the current transaction):
No more than US$ 14,178,512
Cumulative shareholding percentage: 100% interest
The status of any restriction of rights (e.g., pledges): None
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Current ratio of securities investment to the total assets: 17.84%
Current ratio of securities investment to the equity attributable to
owners of the parent: 24.94%
Working capital: NTD 1,593,781 thousand.
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
Long-term Investment
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:Yes
18.Date of the Board of Directors’ resolution:2025/01/14
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:N/A
21.Name of the CPA firm:N/A
22.Name of the CPA:N/A
23.License no.of the CPA:N/A
24.Whether the transaction involved in change of business model:No
25.Details on change of business model:N/A
26.Details on transactions with the counterparty for the past
year and the expected coming year:N/A
27.Source of funds:2025 Cash Capital Increase
28.Any other matters that need to be specified:
The Board of Directors of Medeologix Corporation held on 2024/1/17,
and 2025/1/14 ,resolved that the respective investment amounts within
one year in Medeologix LLC shall be no more than US$3,000,000 and
US$3,000,000. The Board authorizes the Chairman to decide the actual
investment amount according to the operating needs of Medeologix LLC. |
|
| 2025/01/14 | 17:19:12 | Medeon, on behalf of its subsidiary Medeologix Corporation, announces the BOD approved the incremental investment to its subsidiary, Medeologix, Inc.. | |
| SEQ_NO |
2 |
Date of announcement |
2025/01/14 |
Time of announcement |
17:19:12 |
| Subject |
Medeon, on behalf of its subsidiary Medeologix Corporation, announces the BOD approved the incremental investment to its subsidiary, Medeologix, Inc.. |
| Date of events |
2025/01/14
|
To which item it meets |
paragraph 20 |
| Statement |
1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Medeologix, Inc.’s common shares.
2.Date of occurrence of the event:2024/01/26~2025/01/14
3.Volume, unit price, and total monetary amount of the transaction:
2024/1/26 transaction volume: 1,500,000 common shares ,
issued price per share: US$1, total monetary amount: US$1,500,000
2024/6/20 transaction volume: 1,500,000 common shares ,
issued price per share: US$1, total monetary amount: US$1,500,000
2024/11/15 transaction volume: 500,000 common shares ,
issued price per share: US$1, total monetary amount: US$500,000
The total transaction amount: The Board of Directors of Medeologix
Corporation has set an investment cap for Medeologix, Inc. at no more
than US$3,000,000 within one year. The actual investment amount is
authorized to be determined by the Chairman of Medeologix Corporation
based on the operational needs of Medeologix, Inc..
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Medeologix, Inc., the 100%-owned subsidiary of Medeologix Corporation
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:
Reason for choosing the related party as the trading counterparty:
The 100%-owned subsidiary of Medeologix Corporation
Previous owner, its relationship with the Company and the trading
counterparty, and the previous date and monetary value of transfer:N/A
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:N/A
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor’s
rights, currently being disposed of, over such related
party:N/A
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):N/A
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:
Terms of delivery or payment: Invest according to Medeologix, Inc.’s
capital needs
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Resolutions of Medeologix Corporation ‘s Board of Directors dated
2024/1/17 and 2025/1/14.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:NT$4.21
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative number of shares held (including the current transaction):N/A
Cumulative monetary amount (including the current transaction):
No more than US$ 14,465,218
Cumulative shareholding percentage: 100%
The status of any restriction of rights (e.g., pledges): None
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Current ratio of securities investment to the total assets: 18.52%
Current ratio of securities investment to the equity attributable to
owners of the parent: 25.90%
Working capital: NTD 1,593,781 thousand.
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
Long-term Equity Investment
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:Yes
18.Date of the Board of Directors’ resolution:2025/01/14
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:N/A
21.Name of the CPA firm:N/A
22.Name of the CPA:N/A
23.License no.of the CPA:N/A
24.Whether the transaction involved in change of business model:No
25.Details on change of business model:N/A
26.Details on transactions with the counterparty for the past
year and the expected coming year:N/A
27.Source of funds:2025 Cash Capital Increase
28.Any other matters that need to be specified:
The Board of Directors of Medeologix Corporation held on 2024/1/17,
and 2025/1/14 ,resolved that the respective investment amounts within
one year in Medeologix, Inc. shall be no more than US$4,000,000 and
US$3,000,000. The Board authorizes the Chairman to decide the actual
investment amount according to the operating needs of Medeologix, Inc.. |
|
| 2025/01/14 | 16:35:35 | Medeon, on behalf of its subsidiary Medeologix Corporation, announces the resolution of BOD on the issuance of common shares. | |
| SEQ_NO |
1 |
Date of announcement |
2025/01/14 |
Time of announcement |
16:35:35 |
| Subject |
Medeon, on behalf of its subsidiary Medeologix Corporation, announces the resolution of BOD on the issuance of common shares. |
| Date of events |
2025/01/14
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2025/01/14
2.Source of capital increase funds:
Issuance of New Shares of common shares for Cash Capital Increase
3.Whether to adopt shelf registration
(Yes, please state issuance period/No): No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance?GNT$224,000,000
Number of shares issued?Gcommon shares 8,960,000 shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time: NA
6.The remaining monetary value and shares after this issuance when
adopting shelf registration: NA
7.Par value per share: NT$10
8.Issue price: NT$25
9.Number of shares subscribed for by or allocated to employees:
10% of the total issued shares, amounting to 896,000 shares,
are reserved for subscription by the Medeologix Corporation’s employees.
10.Number of shares publicly sold: NA
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
The remaining number of shares to be issued will be subscribed in
proportion to the shareholders and their shareholdings as recorded
in the shareholders’ register on the basis of the subscription date.
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
Shares renounced by original shareholders and employees, or fractional
shares that are less than one share, are authorized to be subscribed
by the Chairman of the Board of Directors through a specific person at
the issue price.
13.Rights and obligations of these newly issued shares:
The rights and obligations of the new shares issued in this cash capital
increase are identical to those of the originally issued common shares.
14.Utilization of the funds from the capital increase:
To increase working capita
15.Any other matters that need to be specified:None |
|
